Dear Colleagues,
PATH is pleased to share with you key findings on the technical and commercial feasibility of stabilizing vaccines. These findings are outlined in a recent guest editorial published in the journal Human Vaccines.
In the editorial, PATH's Debra Kristensen, group leader of Vaccine Technologies, and Dexiang Chen, senior technical officer, reflect on nearly eight years of work with 33 collaborators to optimize the heat- and freeze-stability of seven vaccines. They also suggest the following recommendations for developing and commercializing vaccines with enhanced temperature stability:
• Stabilization efforts should be integrated into early vaccine development.
• There are circumstances where it makes sense to stabilize existing vaccines.
• Freeze stabilization is possible for vaccines containing aluminum adjuvant.
• Heat stabilization requires a customized approach, and results will be variable.
• The full benefits of heat-stable vaccines will only be realized after programmatic and policy changes are made to storage guidelines.
• Improvements in vaccine heat stability are inextricably tied to product format, and careful consideration should be given to the end-product attributes and priorities during vaccine development. Some heat-stability improvements result in inferior product formats while others enable new, beneficial formats.
• Products with enhanced stability can benefit both vaccine producers and purchasers.
For more information on PATH's work in vaccine stabilization, please visit: http://www.path.org/projects/vaccine-stabilization.php
Thank you,
Amy Wales
PATH
- Page :
- 1
There are no replies made for this post yet.